Malignant Lymphomas and Hodgkin’s Disease: Experimental and Therapeutic Advances

1. Front Matter

   Pages I-XV

   PDF

2. Immunopathology

   1. Front Matter

      Pages 1-1

      PDF

   2. The cell of origin of Hodgkin’s disease

      • C. W. Berard

      Pages 3-6

   3. Hodgkin’s disease: Further information derived from cell lines

      • H. Burrichter, M. Schaadt, C. Kortmann, W. Heit, E. Schell-Frederick, H. Stein et al.

      Pages 7-15

   4. Origin and biologic function of Reed-Sternberg cells

      • R. I. Fisher, S. E. Bates, D. J. Volkman, V. Diehl, T. T. Hecht, D. L. Longo

      Pages 17-24

   5. Immunologic phenotypes of non-Hodgkin’s lymphomas: Correlation with morphology and function

      • E. S. Jaffe, O. J. Cossman, L. M. Neckers, R. M. Braziel, C. R. Simrell

      Pages 25-36

   6. Non-Hodgkin’s lymphoma with multilobated nuclei is not a distinct pathologic entity

      • Ph. M. Kluin, S. C. J. Van Der Putte, H. J. Schuurman, L. H. P. M. Rademakers, S. Poppema, J. A. M. Van Unnik

      Pages 37-44

   7. Burkitt’s lymphoma: Multiparametric analysis of 55 cell lines with special reference to morphometry

      • P. Felman, P. A. Bryon, O. Gentilhomme, J. P. Magaud, A. M. Manel, B. Coiffier et al.

      Pages 45-55

   8. Regulation of T-cell colony formation in the absence of added growth factors, in patients with T-cell malignancies

      • V. Georgoulias, M. Allouche, C. Jasmin

      Pages 57-69

3. Cytogenetics

   1. Front Matter

      Pages 71-71

      PDF

   2. Banded chromosome abnormalities in non-Hodgkin’s lymphoma. Correlations with morphology, immunologic phenotype and clinical course

      • C. D. Bloomfield, D. C. Arthur, E. G. Levine, G. Frizzera, K. J. Gajl-Peczalska, T. W. Lebien et al.

      Pages 73-80

   3. Chromosomal aberrations in leukemic low-grade malignant B-cell lymphoproliferative neoplasias

      • G. Gahrton, G. Juliusson, K. H. Robert, K. Friberg, L. Zech

      Pages 81-87

   4. Chromosome abnormalities in Burkitt lymphoma and Burkitt-type acute lymphoblastic leukemia

      • A. De La Chapelle

      Pages 89-99

   5. DNA content and proliferation in non-Hodgkin’s lymphoma: Flow cytofluorometric DNA analysis in relation to the Kiel classification

      • B. Christensson, B. Tribukait, P. Biberfeld

      Pages 101-114

   6. Oncogenes in human neoplasms

      • G. M. Cooper

      Pages 115-122

   7. Stage specific transforming genes in lymphoid neoplasms

      • M. A. Lane, H. A. F. Stephens, M. B. Tobin, K. Doherty

      Pages 123-127

4. Biochemical markers

   1. Front Matter

      Pages 129-129

      PDF

   2. DNA synthetic and degradative pathways in malignant lymphomas

      • A. V. Hoffbrand, A. D. Ho

      Pages 131-139

   3. Enzymes involved in adenosine metabolism in normal or leukemic lymphocytes

      • J. C. Mani, J. C. Bonnafous, G. Clofent, J. Favero, A. Gartner, J. Dornand

      Pages 141-149

   4. Purine metabolism in normal and pathologic lymphoid cell differentiation

      • H. J. Schuurman, J. P. R. M. Van Laarhoven, G. C. De Gast

      Pages 151-161

Malignant lymphomas remain a fascinating research topic for clinicians as well as basic scientists. Rapidly increasing technical sophistication, ex­ panded knowledge and broader implications of new findings underline the need for a forum to integrate the latest developments in the multiple areas involved in the challenging study of lymphoid malignancies. This volume includes contributions of renowned experts and is based on a selection of papers presented at the Second International Conference on Malignant Lymphomas that was held in Lugano, Switzerland, in June 1984. Updated information is provided on various experimental fields including cell biolo­ gy, immunology, genetics and cell biochemistry. Particular attention has been given to special clinical entities such as the lymphomas associated with the Acquired Immune Deficiency Syndrome. Recent advances in the treat­ of Hodgkin's disease, ncin-Hodgkin's lymphomas and childhood lym­ ment phomas are highlighted with emphasis on growing experience with new therapeutic approaches including monoclonal antibodies and bone marrow transplantation. The contents of the volume reflect and translate numerous avenues of exploration. While there might be some unavoidable overlap, most appear essentially complementary. The intent of the Program Committee of the Second International Conference on Malignant Lymphomas was to promote further interactions between all those who are devoting major efforts to elucidate the nature of these diseases or their optimal therapy. This volume will hopefully amplify this objective. The Editors wish to thank the contributors for delivering the manuscripts on schedule.

• Staging
• biopsy
• cell
• classification
• clinical trial
• cytogenetics
• genetics
• interferon
• leukemia
• liver
• lymphocytes
• lymphoma
• pathology
• stem cell
• transplantation

• Division of Oncology, Ospedale San Giovanni, Bellinzona, Switzerland

  Franco Cavalli

• Istituto Nazionale, per lo Studio e la Cura dei Tumori, Milano, Italy

  G. Bonadonna

• Pharmaceutical Research & Development Division, Bristol-Myers Company, Syracuse, USA

  Marcel Rozencweig

Policies and ethics